Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Musculoskeletal  |  Oncology

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Acute Myeloid Leukemia Clinical Trials

A listing of Acute Myeloid Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (92) clinical trials

Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

This phase I/2 trial studies the side effects and best dose of activated natural killer cells in treating patients with relapsed or refractory acute myeloid leukemia and myeloid dysplastic syndromes. Giving chemotherapy before a donor natural killer cell infusion helps stop the growth of cancer cells. It may also stop ...


Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients

To determine the efficacy of decitabine followed by Rapamycin in previously untreated elderly patients not able to receive standard chemotherapy or in patients with relapsed or refractory AML, through measurement of Complete Remission (CR), Complete Remission Incomplete Platelet Recovery (CRp), Partial Remission (PR), and event free and overall survival (Arm ...


A Phase I/II Trial of the MUC1 Inhibitor GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase I The maximum tolerated dose (MTD) will be determined in the phase I section of the trial. Patients who fulfill eligibility criteria will be entered into the trial to GO-203-2c. After the screening procedures confirm participation in the research study. The investigators are looking for the highest dose of ...


FLYSYN in MRD Positive AML

Cohort 1: Patient 1-3: FLYSYN 0.5 mg/m body surface area (BSA) day 1 Cohort 2: Patient 4-6: FLYSYN 0.5 mg/m body surface area (BSA) day 1 FLYSYN 1.0 mg/m BSA day 2 Cohort 3: Patient 7-9: FLYSYN 0.5 mg/m body surface area (BSA) day 1, FLYSYN 4.5 mg/m BSA day ...


Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed

PRIMARY OBJECTIVES: I. To identify a safe dose of guadecitabine in combination with atezolizumab and to assess the safety and tolerability of the combination in patients with myelodysplastic syndrome (MDS) who are refractory to or have lost their confirmed response to one or more hypomethylating agents (HMAs) and in patients ...


Efficacy and Safety of Chidamide in CBF Leukemia

In this open-label, randomized, prospective clinical trial, CBF AML(including AML1-ETO or CBF-MYH11 mutated patients) patients who have reached CR are randomised into two groups and receive HDAC or high dose of cytarabine plus chidamide. In experimental group, patients receive cytarabine at a dose of 3g//d on the first, third and ...


Filgrastim Cladribine Cytarabine and Mitoxantrone With Sorafenib Tosylate in Treating Patients With Newly-Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

PRIMARY OBJECTIVES: I. To assess the maximum tolerated dose (MTD) of sorafenib (sorafenib tosylate) used in combination with dose-intensified mitoxantrone (mitoxantrone hydrochloride) as part of the G-CSF, cladribine, cytarabine and mitoxantrone hydrochloride (G-CLAM) regimen in adults with newly-diagnosed acute myeloid leukemia (AML)/high-risk myelodysplastic syndromes (MDS). (Phase 1) II. To determine ...


A clinical trial sponsored by University of Arizona for a research study for the treatment of Juvenile Myelomonocytic Leukemia, MALT Lymphoma, Diffuse Large B-Cell Lymphoma, Acute myeloid leukemia, Burkitt's Lymphoma, Hodgkin's Disease, MYELODYSPLASTIC SYNDROME, Gray Zone Lymphoma, childhood ALL, follicular lymphoma, Chronic myeloid leukemia, Lymphoma, Preleukemia, Mantle cell lymphoma

This study will follow the standard-of-care bone marrow transplant (BMT), with the only exception being to gradually substitute post-transplant cyclophosphamide (on day +4 after BMT) with bendamustine. Three dose levels are planned for the phase I component of the study, consisting of a combination of sequentially reduced doses of cyclophosphamide ...


Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia

While growing the NK cells from the blood in the lab, mismatched T cells may also grow, which can cause a reaction against normal tissue called graft-vs-host disease (GvHD). In the lab, the T cells will be removed from the cell product using special magnets and antibody-coated magnetic beads. The ...


Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects With Resistant Acute Myeloid Leukemia (AML)(UF-AML-CE-101)

This study will look at: any side effects that occur, the effectiveness of the study drug, and how your disease reacts to ciprofloxacin in combination with etoposide. This study will try to find the highest tolerated dose of ciprofloxacin without causing serious side effects. This study will also look to ...